Result of Psorlyn tablet and Psorlyn oil in Psoriasis(skin disease).

Clinical Study To Evaluate The Efficacy And Safety Of Psorlyn Tablet And Psorlyn Oil In Psoriasis W.S.R. Kitibha

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/033243

Enrollment

Registered

2021-04-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L988- Other specified disorders of the skin and subcutaneous tissue

Interventions

Intervention1: Psorlyn tablet & Psorlyn oil: DOSE - Psorlyn tablet -1tablet TID (500mg) LOCAL APPLICATION – Psorlyn oil will be used in adequate amount for two times on affected area, after 10 mi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children age group between 10 – 16 years of either sex. 2. Children having classical sign and symptom and diagnosed as psoriasis. 3. Patient should be capable of obeying the instruction related to course of therapy.

Exclusion criteria

Exclusion criteria: 1. Patient with k/c/o any chronic systemic illness and allergic disorders. 2. Patient with k/c/o any other chronic skin disorder except psoriasis. 3. Patient not fulfilling the inclusion criteria. 4. Patient/Attendant not willing to give written consent for participation in the research study.

Design outcomes

Primary

Measure	Time frame
Change in Pasi score.Timepoint: 3 months	—

Secondary

Measure	Time frame
To evaluate the safety of trial drug (Tablet Psorlyn & Oil Psorlyn). Timepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Shrinidhi kumar k

National Institute of Ayurveda, Jaipur

drrknagar@gmail.com9414062099

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026